Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Still a Buy?

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $28.44 and last traded at $27.6790, with a volume of 137106 shares trading hands. The stock had previously closed at $25.59.

Analyst Ratings Changes

A number of analysts recently weighed in on ANRO shares. BTIG Research increased their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Robert W. Baird dropped their price target on shares of Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Finally, Wedbush decreased their price objective on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a report on Thursday, April 2nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Stock Up 5.1%

The stock has a market cap of $859.30 million, a P/E ratio of -12.31 and a beta of 2.01. The stock’s 50-day moving average is $21.37 and its 200-day moving average is $16.67. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. As a group, research analysts anticipate that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several hedge funds have recently modified their holdings of ANRO. XTX Topco Ltd raised its stake in shares of Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares in the last quarter. Ikarian Capital LLC grew its holdings in Alto Neuroscience by 368.2% during the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock worth $9,167,000 after acquiring an additional 405,000 shares during the period. Vestal Point Capital LP raised its position in Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares in the last quarter. Wellington Management Group LLP bought a new stake in Alto Neuroscience in the fourth quarter worth about $1,228,000. Finally, Perceptive Advisors LLC lifted its holdings in Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after acquiring an additional 1,629,027 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.